Recently, AngioDynamics (ANGO) expanded its product portfolio by launching two products − the total abscession nephrostomy drainage catheter and the micro-introducer kits with a new stiffened introducer option.
 
AngioDynamics completed the total abscession family of products by launching the nephrostomy drainage catheter.  The family of products, inclusive of general drains and a biliary drainage catheter, provides physicians and hospitals a full range of choice from a solitary source.
 
The new drainage catheter is used in percutaneous nephrostomy drainage.  This minimally invasive procedure allows a physician to place the catheter through the skin in the back into the kidney thereby relieving pressure on the organ from a back-up of urine.
 
The launch of a new family of micro-introducer kits by the company is also positive news for physicians. The micro-introducers make the insertion of a guidewire or catheter into a patient during minimally invasive procedures easier for doctors.
 
AngioDynamics, founded in 1988 and headquartered in Queensbury, New York, is engaged in the designing, development, manufacture and marketing of therapeutic and diagnostic devices to treat peripheral vascular disease and other non-coronary diseases. Peripheral vascular disease is a condition in which the arteries or veins that carry blood to and from the legs, arms and non-cardiac organs (kidney, intestines and brain) become narrowed, obstructed or ballooned. The products are sold to interventional radiologists and other physicians for minimally invasive therapies, in the United States and abroad.
 
AngioDynamics has a leading market share in several of its operating segments including angiographic products and thrombolytic catheters and products. The company’s product line rivals larger competitors such as Boston Scientific Corp. (BSX) and CR Bard Inc. (BCR) in both depth and spread. The market served by AngioDynamics is in excess of $1 billion, and is continuing to grow impressively.
 
Currently, we are Neutral on AngioDynamics.
Read the full analyst report on “ANGO”
Read the full analyst report on “BSX”
Read the full analyst report on “BCR”
Zacks Investment Research